NZ330995A - Generation of T cells mediating an immune response and use for treating cancer - Google Patents
Generation of T cells mediating an immune response and use for treating cancerInfo
- Publication number
- NZ330995A NZ330995A NZ330995A NZ33099597A NZ330995A NZ 330995 A NZ330995 A NZ 330995A NZ 330995 A NZ330995 A NZ 330995A NZ 33099597 A NZ33099597 A NZ 33099597A NZ 330995 A NZ330995 A NZ 330995A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- tumour
- group
- human
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 9
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 4
- 230000028993 immune response Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 201000001441 melanoma Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 abstract 1
- 125000001894 2,4,6-trinitrophenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O 0.000 abstract 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- -1 dinitrophenyl Chemical group 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
T cells, compositions, and methods for treating cancer. The methods include a method of generating T cells capable of infiltrating a tumour of a human and participating in an immune response against the tumour; and a method of treating cancer comprising administering to a human afflicted with a tumour a therapeutically effective amount of T cells that mediate tumour regression, the T cells having been either isolated from the tumour of the human after immunization of the human with a composition comprising hapten-modified tumor cells and/or expanded in vitro from T cells thus isolated. Malignant tumour cells selected from the group melanoma, lymphoma, adenocarcinoma, sarcoma and non-solid tumours. The use is selected from the group consisting of melanoma, ovarian, colon, breast, rectal, lung, kidney, prostate cancer and leukemia. The adjuvant used is selected from the group consisting of Bacille Calmette-Guerin, Q-21 and detoxified endotoxin. The hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N'-(sulfonic 1-naphtyl) ethylene diamine, trinitrobenzenesulfonic acid and dinitrobenzene-S-mustard.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2700296P | 1996-10-04 | 1996-10-04 | |
| PCT/US1997/015741 WO1998014206A1 (en) | 1996-10-04 | 1997-10-02 | T cells mediating an immune response and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ330995A true NZ330995A (en) | 2000-12-22 |
Family
ID=21835095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ330995A NZ330995A (en) | 1996-10-04 | 1997-10-02 | Generation of T cells mediating an immune response and use for treating cancer |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0871480A4 (en) |
| AU (1) | AU4976697A (en) |
| CA (1) | CA2242590A1 (en) |
| IL (1) | IL125747A0 (en) |
| NZ (1) | NZ330995A (en) |
| PL (1) | PL328790A1 (en) |
| WO (1) | WO1998014206A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301174A (en) * | 1998-04-09 | 2001-06-27 | 托马斯杰斐逊大学 | Method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| ATE401096T1 (en) * | 1998-05-04 | 2008-08-15 | Univ Jefferson | USE OF HAPTEN-TREATED TUMOR CELLS AND EXTRACTS |
| WO2000057911A2 (en) | 1999-03-16 | 2000-10-05 | Thomas Jefferson University | Hapten-conjugated mammalian cells and methods of making and using thereof |
| US7297330B2 (en) * | 2000-02-04 | 2007-11-20 | Thomas Jefferson University | Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| CA2489076A1 (en) | 2002-06-10 | 2003-12-18 | Avax Technologies Inc. | Cryopreservation of haptenized tumor cells |
| EP1694865A4 (en) * | 2003-12-12 | 2007-06-06 | Bayer Pharmaceuticals Corp | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3806565A1 (en) * | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | VIRUS-MODIFIED TUMOR VACCINES FOR THE IMMUNOTHERAPY OF TUMOR METAL KEYS |
| IE922233A1 (en) * | 1991-07-10 | 1993-01-13 | Augusto C Ochoa | Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity |
| ES2224113T5 (en) * | 1994-02-16 | 2009-05-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | ANTIGEN POLYPEPTIDE ASSOCIATED WITH MELANOMA, EPITHOPOS OF THE SAME AND VACCINES AGAINST MELANOMA. |
| KR19990022592A (en) * | 1995-06-07 | 1999-03-25 | 아브람 엠. 골드핑거 | Tumor cell extracts modified with hapten and methods for treating or screening cancer |
-
1997
- 1997-10-02 IL IL12574797A patent/IL125747A0/en unknown
- 1997-10-02 PL PL97328790A patent/PL328790A1/en unknown
- 1997-10-02 NZ NZ330995A patent/NZ330995A/en unknown
- 1997-10-02 AU AU49766/97A patent/AU4976697A/en not_active Abandoned
- 1997-10-02 CA CA002242590A patent/CA2242590A1/en not_active Abandoned
- 1997-10-02 WO PCT/US1997/015741 patent/WO1998014206A1/en not_active Application Discontinuation
- 1997-10-02 EP EP97912648A patent/EP0871480A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PL328790A1 (en) | 1999-02-15 |
| EP0871480A4 (en) | 2001-04-04 |
| IL125747A0 (en) | 1999-04-11 |
| CA2242590A1 (en) | 1998-04-09 |
| AU4976697A (en) | 1998-04-24 |
| EP0871480A1 (en) | 1998-10-21 |
| WO1998014206A1 (en) | 1998-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122817T1 (en) | NEW ANTI-IL 13 ANTIBODIES AND THEIR USES | |
| Mew et al. | Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. | |
| ATE425749T1 (en) | TREATMENT OF HER-2/NEW OVEREXPRESSION-ASSOCIATED CANCER | |
| MXPA03001389A (en) | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies. | |
| NO993654L (en) | Kit for inhibiting cancer growth, comprising a chemotherapeutic agent and a benzimidazole and optionally an enhancer | |
| NZ524036A (en) | Treatment and diagnosis of cancer | |
| BR9508245A (en) | Method to inhibit cancer metastasis by oral administration of soluble modified citrus pectin | |
| MXPA03000527A (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer. | |
| DE69834024D1 (en) | TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF SPECIFIC CANCER TYPES | |
| NZ512247A (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
| MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
| ATE260666T1 (en) | CELLULAR VACCINE AND USE THEREOF FOR THE TREATMENT OF MALIGNANT SOLID TUMORS | |
| WO1997035021A3 (en) | Prostate specific antigen oligo-epitope peptide | |
| IT1164244B (en) | PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST IN DETOXIFIED ENDOTOXIN PART AND ITS THERAPEUTIC USE | |
| NZ330995A (en) | Generation of T cells mediating an immune response and use for treating cancer | |
| EP1272636B8 (en) | A gene differentially expressed in breast and bladder cancer and encoded polypeptides | |
| NZ504938A (en) | Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen | |
| DE69232395D1 (en) | ANTI-TUMOR VACCINE | |
| NZ237688A (en) | Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment | |
| Khan et al. | Synthetic polyribonucleotides: current role and potential use in oncological practice | |
| UY26266A1 (en) | ANTIGEN ASSOCIATED WITH TUMORS (R11) LAW 17164 | |
| Yasumoto et al. | Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients | |
| AU1991097A (en) | Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases | |
| HUT43495A (en) | Process for production and compound for treating of cancer and beningn tumor | |
| ZA200106725B (en) | Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response. |